| Abbott submits new FDA application for cancer drug | Posted on 15/03/2010 in Pharmaceutical Company Product News Abbott is submitting a supplemental new drug application to the Food and Drug Administration (FDA) for a new specification of its prostate cancer drug Lupron Depot.
The regulator has already accepted the application for review and will now be evaluating the new six-month 45 mg formulation for possible approval.
This treatment has already been made available in one-month, three-month and four-month depot formulations and functions by suppressing the production of the hormone testosterone.
Dr Eugene Sun, vice-president of global pharmaceutical development at Abbott, stated that approval of the application would bring benefits to sufferers looking to manage their condition.
He said: "Abbott is seeking approval for a new six-month formulation to provide greater convenience and dosing flexibility to physicians and patients who could benefit from this medication."
Last week, the company announced that it will be acquiring biotechnology company Facet Biotech to expand its offerings in the fields of immunology and oncology.Other news stories from 15/03/2010
Read more in the Zenopa News Archive
How this news is generated
|  |
|
